Stromal cell effects on melanoma cell drug response by Della Penna, Greg
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2013
Stromal cell effects on melanoma
cell drug response
https://hdl.handle.net/2144/12086
Boston University
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
Thesis 
 
 
 
 
STROMAL CELL EFFECTS ON MELANOMA CELL DRUG  
 
RESPONSE 
 
 
 
by 
 
 
 
GREG DELLA PENNA 
 
 
B.S., Boston College, 2011 
 
 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Arts 
 
2013 
   
Approved by 
 
 
 
 
 
 
 
 
 
First Reader   
  
 Matthew A. Nugent, Ph.D.  
 Professor of Biochemistry, Biomedical Engineering and     
      Ophthalmology  
 
 
 
 
 
 
 
 
Second Reader   
  
 Constantine Mitsiades, M.D., Ph.D. 
 Assistant Professor of Medicine 
 Harvard Medical School 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iii 
DEDICATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For Brendan Greve 
 
 iv 
ACKNOWLEDGEMENTS 
I would like to thank Dr. Constantine Mitsiades, Dr. Eugen Dhimolea, Megan 
Bariteau, Dr. Catriona Hayes, Dr. Douglas McMillin, Dr. Ana Acuna, Dr. Richard 
Groen, Jeffrey Sorrell, and everyone else at the Dana Farber Cancer Institute 
that helped me with my research.  Thank you all for your guidance, instruction, 
and friendship over the past year.  
 
 
 
 v 
STROMAL CELL EFFECTS ON MELANOMA CELL DRUG  
 
RESPONSE 
 
 
 
GREGORY DELLA PENNA   
 
Boston University School of Medicine, 2013 
 
Major Professor: Matthew A. Nugent, Ph.D., Professor of Biochemistry, 
Biomedical Engineering and Ophthalmology     
 
ABSTRACT 
 
Objective:  Melanoma is currently one of the deadliest forms of skin disease in 
the United States. However in the past decade there have been significant 
advances in treatment.  Among the most promising recent developments, 
inhibitors of the serine/threonine-protein kinase B-Raf (BRAF inhibitors) such as 
vemurafenib show great promise and have been shown to increase the median 
survival of patients with melanoma cells that harbor a mutation of the BRAF 
gene.  While BRAF inhibitors and other treatment therapies have much potential, 
more needs to be done to improve treatment. 
 As with other cancers, a major hurdle in the treatment of melanoma is the 
eventual tumor resistance to drug therapy.  Accessory cells are thought to play a 
large role in mediating tumor resistance to drug treatment.  Stromal cells have 
been known to release cytokines and growth factors that aid in cancer 
proliferation.  They can also expression adhesion molecules that further help to 
aid cell growth and tumor development.  It has also been demonstrated that 
these accessory cells can significantly alter cancer cell drug response as a result 
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of the factors they release or express on their surface.  In this study we 
hypothesize that certain anti-cancer drugs will behave differently against 
melanoma cell line A375 in the presence versus the absence of stromal cells. 
Methods:  Melanoma cell line A375 was grown on 384 well plates in the 
presence or absence of different stromal cell lines.  A number of different drugs 
were screened using Compartment-Specific Bioluminescence Imaging to 
determine if there was a difference in A375 proliferation after drug treatment in 
the presence versus absence of accessory cells.  After an initial screen, a few 
drugs were chosen to generate dose-response curves to determine if different 
drugs had different effects at various doses in the presence or absence of 
stromal cells. 
Results:  An initial screen involving 81 FDA approved oncology drugs showed 
that a number of drugs had different effects on A375 cells in the presence versus 
absence of stromal cells.  A follow-up screen of 24 compounds identified six 
different drugs that were effective at killing A375 cells.  Four of these drugs, as 
well as vemurafenib, crizotinib, and bortezomib were chosen to be used in the 
generation of drug dose-response curves to look for differences in drug action in 
the presence of stromal cells.  Of these drugs, cytarabine, bortezomib, and 
vemurafenib showed the most significant changes in drug response in the 
presence versus absence of stromal cells. 
Conclusion:  In this study, we observed that some drugs behave in a significantly 
different manner on A375 melanoma cells in the presence versus absence of 
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stromal cells.  By using Compartment-Specific Bioluminescence Imaging (CS-
BLI) we were able to determine exactly how much cellular proliferation levels 
were altered. We believe that these results indicate that further study on 
intercellular interactions on melanoma cell drug response is needed.  
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INTRODUCTION 
  
 Each year over 122,000 people worldwide are diagnosed with some form 
of melanoma and about 65,000 people per year die from the disease.  While 
there have been many advancements in therapy, melanoma remains the most 
dangerous form of skin disease.[1] 
Melanoma is the malignant proliferation of melanocytes.  Melanocytes are 
cells that produce the pigment known as melanin.  Melanin gives rise to skin as 
well as hair color.  Melanoma can originate anywhere melanocytes can be found.  
It can sometimes be located in the small intestine, large intestine, lungs and 
other internal organs.[2] However, by far most cases of melanoma present in the 
skin, and less frequently, the eyes.  When found on the skin, melanoma typically 
presents as an asymmetrical dark mole or growth. 
 While there are a few different types of melanoma, the four main types of 
melanoma include superficial spreading melanoma, nodular melanoma, lentigo 
maligna melanoma, and acral lentiginous melanoma. [2] Superficial spreading 
melanoma (SSM) is the most common form of melanoma found on the skin.  
SSM is frequently found on sun-exposed skin.  Commonly originating from pre-
neoplastic lesions, this type of melanoma typically presents in two stages: a) first, 
a radial growth phase, and b) second, a vertical growth phase, where the 
population of neoplastic cells begins to develop malignant features.  Like SSM, 
lentigo maligna melanoma tends to be located on chronically sun-exposed skin.  
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Originating from non-invasive lentigo maligna (skin growths), lentigo maligna 
melanoma generally presents as dark raised nodules on the skin.[2] Nodular 
melanoma is more aggressive than other types of melanoma.  Nodular 
melanoma often has a rapid vertical growth phase and can present in locations 
showing no previous abnormal growths.  In some cases, the growth does not 
exhibit dark pigment, thus delaying detection, which can be especially deadly.  
The last major form of melanoma is acral lentiginous melanoma (ALM).  ALM can 
be one of the most difficult types of melanoma to identify.  It can present on 
areas of the body that are not exposed to high levels of sunlight such as beneath 
nail beds, in the mouth, and on the soles of feet.  This type of melanoma is the 
most common melanoma to affect people of Asian and African descent.[1] 
 Melanoma can be caused by a variety of factors.  One of the most 
significant causes of melanoma is overexposure to UV radiation.[3] Individuals 
that have chronic sun damage from ultraviolet light demonstrate a significantly 
higher prevalence of melanoma.  This can be from both UV light from the sun as 
well as tanning beds.  In addition to overexposure to UV radiation, other 
significant risk factors include prolonged presence at high altitudes, fair skin, light 
hair, moles, weakened immune system, familial history of the disease as well as 
prior xeroderma pigmentosa.[2] Other genetic predispositions to the development 
of melanoma include mutations in MC1R or CDKNA2, which are associated with 
significantly higher rates of developing melanoma.[4] 
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 There are a variety of ways in which an individual can improve his or her 
chances of preventing the disease.  Perhaps the best way of preventing 
melanoma is to minimize exposure to UV radiation.  Avoiding tanning beds as 
well as using sunscreen that blocks both UVA and UVB radiation significantly 
reduces one’s chance of developing the disease.  Wearing clothes that block 
sunlight can also help to prevent the disease.[2] It is important that individuals 
constantly monitor themselves for abnormal growths.  Professional screens can 
also help in reducing the chances of malignancy.   
 
Treatment 
Despite methods of prevention, many individuals will develop malignant 
melanoma over the course of their lifetime.  Treatment for the disease can be 
administered via multiple approaches.  At present, the most effective treatment 
for the disease remains to be surgery.  Surgical excision of tumors is the best 
way for completely curing the disease, as long as it has not disseminated away 
from the primary site.[5] In some cases, sentient lymph nodes can also be 
excised in order to reduce chances of further spreading.[6] However, when 
melanoma has spread to other organs, surgical resection becomes less and less 
effective.   
When surgery no longer remains feasible for curing the disease, other 
treatment options do exist.  For instance, as with other cancers, radiation therapy 
can be administered, but it is generally limited to melanomas that have spread 
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locally.  For those cases that require a more aggressive treatment, there are a 
variety of different chemotherapeutic strategies as well as immunotherapy 
options that are used to combat the disease.  In the past, the two most common 
drugs that were used for melanoma treatment were dacarbazine and high-dose 
interleukin 2.[7] However both of these treatment strategies have their limitations.  
Dacarbazine has a very low response rate (10-15%) as well as a low overall 
mean survival.  High dose interleukin-2 (HDIL2) works on an even smaller 
percentage of patients (5-10%).  HDIL2 also has major side effects.[7] 
 Over the past decade, there has been a significant improvement in 
immunotherapy.  One reason why immunotherapy seems to be so promising in 
melanoma is the highly immunogenic nature of melanoma tumors.  Melanoma 
tumors exhibit very high levels of tumor-infiltrating lymphocytes and this 
characteristic has encouraged extensive research in immunotherapy.  One such 
drug that shows promise is ipilimumab.  Ipilimumab is a fully human IgG1 
monoclonal antibody that acts by blocking CTLA-4, a negative T cell regulator.[7] 
By blocking the negative regulator, T cells become increasingly active and can 
diminish size and number of tumors more effectively.  With ipilimumab, median 
overall survival was increased by 3-4 months. However one drawback of 
ipilimumab is its low overall response rate (between 10-15%).[7]   
 There has been much research as of late to try and improve the 
effectiveness of ipilimumab.  Some researchers suggest that a higher dose than 
the FDA approved 3 mg/kg could help lead to increased rate of response.[7] 
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Other researchers believe that a drug combination therapy including ipilimumab 
may be the best way to increase efficacy and rate of response. A study 
conducted in June 2011, showed that ipilimumab administered in combination 
with standard dacarbazine showed an added improvement in overall survival 
time.[8] Other compounds that appear to increase the average response rate 
when combined with ipilimumab include bevacizumab and temozolamide.  Both 
of these drugs demonstrated higher response rates in phase 2 studies when 
combined with ipilimumab versus using ipilimumab alone.[8] 
 In addition to ipilimumab, other immunotherapies are currently being 
developed.  One of the most promising immunotherapies is adoptive cell therapy.  
Taking advantage of the high levels of tumor-infiltrating lymphocytes found in 
melanoma tumors, adoptive cell therapy involves extraction of these TIL’s.  
These cells are then expanded and injected back into the patient.  ACT has been 
shown to have a response rate of around 30%. However when combined with 
lymphodepletion of regulatory T cells, the response rates have increased to over 
70%.[9] Aside from lymphodepletion, other adjunct therapies are also being 
evaluated.  Some investigators are trying to genetically modify autologous T cells 
not found in the tumor to express antigens that can recognize and target 
melanoma cell specific antigens.  Other studies have reported that by pretreating 
individuals with interferon gamma, increased tumor immunogenicity develops 
which could result in a higher overall response rate.[7] 
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BRAF 
 One of the most significant advances in the past few years for the 
treatment of melanoma is the development of BRAF inhibitors.  The BRAF gene 
is an important part of the MAP kinase signaling pathway that can lead to cell 
growth and is an important pathway for tumorigenesis in melanoma as well as a 
few other types of cancer types.  BRAF is responsible for producing a protein 
called B-Raf.  B-Raf is a serine/threonine protein kinase that helps activate cell 
growth, division and secretion.[10] In cutaneous melanoma, BRAF mutations 
have been detected in over 40% of patients.  The vast majority of BRAF 
mutations are due to a substitution of glutamate for valine at amino acid 600 
(V600E).[11] The substitution at this site leads to chronic activation of the MAP 
kinase pathway and therefore provides a means for increased growth of many 
melanoma tumors.  
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Figure 1: Overview of the MAPK pathway 
The MAPK pathway is an important growth pathway for cell survival and 
proliferation.  As seen above, BRAF plays an important part in the pathway.  
 
Early attempts at mutant BRAF inhibition used a BRAF inhibitor known as 
sorafenib.  Sorafenib had significant side effects however due to its poor 
selectivity against BRAF mutants and its activity against many other targets.[7] 
Recently, BRAF inhibitors that have demonstrated a much greater specificity for 
BRAF mutants have been developed.  In 2011, the FDA approved for use in 
patients with metastatic melanoma a BRAF inhibitor, developed by Plexxikon 
called vemurafenib (also known as PLX4032).  In a phase 1 trail, vemurafenib 
proved to be efficacious in over 80% of patients who presented with a V600E 
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mutation.[12] While not yet approved by the FDA, vemurafenib also appears to 
have some effect in patients with a V600K mutation (the valine is replaced by 
lysine).[7] For patients with the V600E mutation that respond to the drug, 
vemurafenib has shown to increase life span for nearly 6 months on average.[7] 
While other selective BRAF inhibitors such as GSK2118436 have been 
developed, vemurafenib remains to be the most common selective BRAF 
inhibitor prescribed to patients with metastatic melanoma. 
 While the drug has been a major breakthrough for the treatment of 
melanoma, resistance to vemurafenib has been the major drawback of treatment. 
After about 6 months, most patients begin to develop major resistance to the 
drug.  One suggested means of developing BRAF resistance is that tumor cells 
begin to produce elevated levels of platelet-derived growth factor receptor-beta 
(PDGFRB).[13] PDGFRB is a tyrosine kinase receptor present on the surface of 
cells that can provide an alternate pathway for cell proliferation in patients treated 
with BRAF inhibitors.  An alternative mechanism proposed for resistance is 
activation of the NRAS pathway.[10] Activation of NRAS leads to a reactivation of 
the MAP kinase pathway and ultimately resistance to vemurafenib. 
 
The Role of Stromal Cells 
Stromal cells have long been known to aid in tissue growth and regulation.  
In normal tissues, neighboring cells found in the ECM as well as other local sites 
help aid in cell growth or destruction based on the needs of the cells or tissues 
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involved.  This is done through the release of a plethora of cytokines and growth 
factors and whose levels change depending on the levels of stress mediated on 
the tissue.  Lately the role of the tumor microenvironment as well as the role of 
stromal cells is becoming an increasingly popular topic in cancer research.  As 
tumors develop and change from normal cells, so do stromal cells.  For many 
cancers, the compounds released by these stromal cells can help aid in growth 
and malignancy.  By releasing compounds such as TNF alpha, EGF, FGF, HGF, 
TGF, PDGF, VEGF, as well as a wide variety of others, stromal cells can have a 
substantial effect on tumor proliferation [14], thus functioning as “accessory 
cells”. 
 Of particular interest in this study is the role which stromal cells and the 
tumor microenvironment play in regards to drug resistance. Previous studies 
have confirmed that stromal cells can significantly affect how cancer cells 
respond to drug treatment. [15] Stromal cells have been shown to increase, as 
well as provide resistance to, drug efficacy.  Stromal cell-mediated resistance to 
drug treatment is a major problem for diverse drug therapies.  By reactivating 
certain growth pathways or activating previously silent growth pathways, stromal 
cells can lead to rapid drug resistance and ineffectiveness. 
 Like in other types of cancers, stromal mediated resistance to drug 
therapy is believed to be a major factor for drug resistance in melanoma.  One 
such study proving this was performed in 2012 by Dr. Ravid Straussman.  In this 
study, Straussman proposed that HGF produced by stromal cells played a 
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significant role in melanoma resistance to selective treatments such as BRAF 
inhibition.[16] 
 
Compartment-Specific Bioluminescence Imaging (CS-BLI) 
One method of determining the effect of stromal cell-mediated resistance 
is through the use of the CS-BLI platform, developed by Dr. Constantine 
Mitsiades and Dr. Douglas McMillin.  CS-BLI is a system that takes advantage of 
luciferase expression.[17] The first step is to make cancer cells stably express 
luciferase.  Once they stably express luciferase they can be grown in culture with 
stromal cells of interest that are luciferase-negative.  Once the cells have been 
plated they can be treated with different agents and after the end of treatment the 
plates can be placed inside a luminometer in order to read the bioluminescence 
of each well.  By reading the amount of light given off by each well, the 
luminometer can then indirectly determine the amount of cells in each well, or at 
least give the user a relative percentage of cells compared to a control as the 
bioluminescence increases linearly with cell number. 
This study has identified multiple compounds that show diminished killing 
efficacy in the presence of stromal cells.  Importantly, the platform can also be 
used to identify any stromal mediated improvements in killing efficacy.[17]  
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The Present Study 
 Since BRAF mutations have recently become such a popular area of 
study we determined that using a BRAF mutant (V600E) would be of the highest 
value.  Therefore we decided to use melanoma cell line A375.   
 In an effort to find as many cases of altered drug response we used a 
variety of chemotherapeutics.  We also used a variety of stromal cell lines as 
multiple lines would produce different growth factors and cytokines and would 
therefore be more likely to elicit drug resistance or sensitization.    
 At present, there are few studies that aim to determine how different 
stromal cells alter melanoma cell drug response.  The purpose of this experiment 
is to demonstrate the importance of stromal cell effects in order to improve 
melanoma study models.  We believe that the addition of stromal cells will alter 
how A375 responds to certain drugs.   
 
Specific Aims   
 In order to determine the effect of stromal cell mediated drug resistance 
and or sensitization to drug treatment on melanoma cells we will: 
1.  Screen melanoma cell line A375 with a variety of FDA-approved 
oncology compounds to identify drugs that show a change in activity in the 
presence of stroma.  At the same time we hope to determine a positive control 
for drug resistance. 
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2.  Establish dose response curves and examine possible stromal cell-
mediated differences in drug response for drugs identified in the FDA Oncology 
Set screen. 
3.  Identify other well-known chemotherapeutics that show significant 
efficacy in killing A375 melanoma cells. 
4. Establish dose response curves for drugs selected previously which 
proved efficacious at killing A375.  Determine if these compounds demonstrate 
any stromal mediated resistance and/or sensitization to drug treatment. 
 
We expect to see: 
1. An initial screen will show that a number of compounds exhibit altered 
drug activity in the presence versus absence of stroma. 
2.  Some drugs selected for further study will generate different dose 
response curves in the presence versus absence of stroma. 
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Methods 
 
Cell Lines and Reagents 
 
Stromal cell lines CCD13LU, CCD1065SK, HU88, and LL86 were all 
obtained from ATCC.  Melanoma line A375 was also obtained from ATCC and 
had previously been transduced to express luciferase. 
 Vemurafenib stock solution was obtained from Sara Buhrlage (Nathanael 
Gray Lab, Dana Farber Cancer Institute).  The FDA oncology set drugs were 
obtained from the National Cancer Institute. The remaining drugs were obtained 
from Sigma-Aldrich and stored at -20°C. 
 
Cell Culture and Plating 
 Cell lines were maintained at 37°C. Cells were grown in Dulbecco’s 
Modified Eagle’s Medium.  Heat-inactivated FBS was added to the media to a 
final concentration of 10%. The media was also supplemented with 100 U/mL 
penicillin and 100 µg/mL streptomycin. 
 Cells were plated using a Thermo Scientific Multidrop Combi.  The cells 
were plated at a ratio of 400 melanoma cells to 1000 stromal cells per well to a 
volume of 45 microliters.  Five microliters of drug in DMSO was added after 24 
hours of co-culture either by repeater pipette or by the JANUS Automated 
Workstation to a final volume of 50 microliters. All experiments were performed 
on white bottom 384 well plates. 
 
 14 
CS-BLI Reading 
To measure bioluminescence, a Biotek luminometer was used.  On the 
day of measurement, 5 microliters of beetle luciferin was added to each well of 
each 384 well plate used.  The plates were allowed to incubate at 37° for 30 
minutes then they were placed in the luminometer to be read. 
 
FDA Oncology Drug Screen 
 The FDA-approved Oncology Set III drug plates (384 wells per plate, 2 
plates) were obtained by the NCI. Two concentrations for each plate (0.1 and 0.5 
micromolar) were also used. A total of 81 compounds were tested.  The 
compounds were stored in 384 well plates with each well containing 20 
microliters of a 10 mM DMSO solution. 
 Cells were plated in co-culture on day one onto 384 white bottom plates 
using a Thermo Scientific Multidrop Combi.  On day 2, 100 nanoliters of drug was 
added to a final concentration of 0.1 or 0.5 micromolar.  Bioluminescence was 
measured using a Biotek luminometer after 72 hours of drug treatment.   
 
In Vitro Testing of Anti-Tumor Agents Against A375 Cells 
 On day one, A375 cells were plated onto 384 well plates using a Thermo 
Scientific Multidrop Combi (45 microliters).  On day two, 10 serial concentrations 
of drug (5 microliters per well) were added to different wells in order to generate 
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dose response curves. Bioluminescence was measured using a Biotek 
luminometer at 24, 48, 72, or 96 hours for the different drugs. 
 
A375 Co-Culture Comparison  
 On day one, A375 cells and either CCD13LU, HS88LU, or LL86 were 
plated in co-culture onto 384 well plates using a Thermo Scientific Multidrop 
Combi (45 microliters).  On day two, 10 different concentrations of drug were 
added to different wells in order to generate dose response curves (5 microliters 
per well).  Bioluminescence was measured using a Biotek Luminometer at 24, 
48, 72, or 96 hours for the different drugs. 
 
 Dose Response Curve Generation 
 For all generation of dose response curves, Graphpad Prism Version 6 
was used.  All curves were normalized to their respective no drug control and 
each data point was the average of at least 4 replicate values. 
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Results 
 
FDA ONCOLOGY SCREEN 
 The screen involved 81 FDA approved oncology drugs.  Certain drugs 
were subject to sensitization and others to resistance in the presence of stroma.  
This was the case for both A375 with CCDK1065SK, as well as A375 with 
CCD13LU.  This was also seen at both the 0.1 micromolar dose as well as the 
0.5 micromolar dose.  In regards to drug mediated sensitization, it appeared that 
vorinostat and tamoxifen HCL showed drug sensitization over the four different 
conditions.  For drug resistance, procarbazine HCL and dasatinib showed 
resistance when co-cultured with stroma (both CCD13LU cells as well as 
CCD1065SK cells).   
 There were some drugs that showed an altered activity in only one of the 
stromal lines.  Sunitinib malate showed slight drug resistance when in the 
presence of CCD1065SK at 0.5 micromolar, but in the presence of CCD13LU 
there was slightly more A375 killing then compared to the no stroma control. 
  
 
 
 
 
 
 
 
 17 
A      
  
D r u g
B
io
lu
m
in
e
s
c
e
n
c
e
 (
%
 o
f 
c
o
n
tr
o
l)
0
5 0
1 0 0
1 5 0
S T R O MA
N O  S T R O MA
P ro c a r b a z in e   H C l 
D a s a tin ib  
V o r in o s ta t 
T a m o x if e n   C itr a te  
 
B 
 
 
D r u gB
io
lu
m
in
e
s
c
e
n
c
e
 (
%
 o
f 
c
o
n
tr
o
l)
0
5 0
1 0 0
1 5 0
S T R O MA
N O  S T R O MA
P ro c a r b a z in e   H C l 
D a s a tin ib  
T a m o x if e n   C itr a te  
V o r in o s ta t 
 
 
 
Figure 2: FDA Oncology Set Plate Screen Using A375 and CCDK1065SK 
Cells.  
The following conditions were used to screen for potential drugs for further 
evaluation. (A) A375 with CCDK1065sk cells were treated with 0.1 micromolar of 
drug. (B) A375 with CCDK1065sk cells were treated with 0.5 micromolar of drug.  
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Figure 3: FDA Oncology Set Plate Screen Using A375 and CCD13LU Cells.  
The following conditions were used to screen for potential drugs for further 
evaluation. (A) A375 with CCD13LU cells were treated with 0.1 micromolar of 
drug. (B) A375 with CCD13LU cells were treated with 0.5 micromolar of drug. 
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IN VITRO TESTING OF ANTI-TUMOR AGENTS AGAINST A375 CELLS 
 Twenty-four anti-cancer drugs were tested on A375.  Each drug was 
individually dosed and then read at 24, 48, 72, or 96 hours to generate dose 
response curves.  The viability of A375 cells in wells receiving drugs were 
compared to the viability of A375 cells in control wells that were not treated with 
any drug.  The compounds then fell into three categories depending on how 
effectively they killed A375.  (A) The first category included drugs that had little 
effect on A375 at the given dosages.  These included MDV3100, bicalutamide, 
dexamethasone, cisplatin, 5-fluoracil, pomalidomide, and lenalidomide.  
Dexamethasone, pomalidomide, and cisplatin even showed a very slight 
increase in viability at higher doses. (B) The next category included those that 
only showed killing at very high doses.  Those included toremifene, raloxifene, 
OHT, fulvestrant, sorafenib, lapatinib, JQ1, erlotinib, melphalan, and doxorubicin.  
Erlotinib even showed an increase in viability at 1 µM followed by a sharp drop 
off in proliferation.  (C) The last category included drugs that showed significant 
killing of A375 even at lower doses.  These drugs included crizotinib, bortezomib, 
cytarabine, epirubicin, gemcitabine, paclitaxel, and vemurafenib.  Of these drugs, 
docetaxel, gemcitabine, and vemurafenib proved to be the most effective at 
killing A375.  Docetaxel and gemcitabine treated A375 showed less than 50% 
proliferation compared to the untreated control at doses as little as 0.001 µM. 
 
 
 
 20 
A 
  
C IS P L A T IN   (4 8 H R S )
C is p la tin   (u M )
B
io
lu
m
in
e
s
c
e
n
c
e
 (
%
 o
f 
c
o
n
tr
o
l)
0 .0 0 0 0 1 0 .0 0 0 1 0 .0 0 1 0 .0 1 0 .1 1 1 0
0
5 0
1 0 0
1 5 0
2 0 0
  4 0 0  A 3 7 5
L E N A L ID O M ID E   (9 6 H R S )
L e n a l id o m id e   (u M )
B
io
lu
m
in
e
s
c
e
n
c
e
 (
%
 o
f 
c
o
n
tr
o
l)
0 .0 0 0 1 0 .0 0 1 0 .0 1 0 .1 1 1 0 1 0 0
0
5 0
1 0 0
1 5 0
2 0 0
  4 0 0  A 3 7 5
5 ‐ F L U O R A C IL   (4 8 H R S )
5 ‐ F lu o r a c i l   ( u M )
B
io
lu
m
in
e
s
c
e
n
c
e
 (
%
 o
f 
c
o
n
tr
o
l)
0 .0 0 0 1 0 .0 0 1 0 .0 1 0 .1 1 1 0 1 0 0
0
5 0
1 0 0
1 5 0
2 0 0
  4 0 0  A 3 7 5
P O M A L ID O M ID E   (9 6 H R S )
P o m a l id o m id e   (u M )
B
io
lu
m
in
e
s
c
e
n
c
e
 (
%
 o
f 
c
o
n
tr
o
l)
0 .0 0 0 1 0 .0 0 1 0 .0 1 0 .1 1 1 0 1 0 0
0
5 0
1 0 0
1 5 0
  4 0 0  A 3 7 5
 
 
 
 
 
 
 
 
 
 
D E X A M E T H A S O N E   (7 2 H R S )
D e x a m e th a s o n e   (u M )
B
io
lu
m
in
e
s
c
e
n
c
e
 (
%
 o
f 
c
o
n
tr
o
l)
0 .0 0 0 1 0 .0 0 1 0 .0 1 0 .1 1 1 0 1 0 0
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
  4 0 0  A 3 7 5
M D V 3 1 0 0   ( 9 6 H R S )
M D V 3 1 0 0   (u M )
B
io
lu
m
in
e
s
c
e
n
c
e
 (
%
 o
f 
c
o
n
tr
o
l)
0 .0 0 0 1 0 .0 0 1 0 .0 1 0 .1 1 1 0 1 0 0
0
5 0
1 0 0
1 5 0
  4 0 0  A 3 7 5
B IC A L U T A M ID E   (9 6 H R S )
B ic a lu ta m id e   (u M )
B
io
lu
m
in
e
s
c
e
n
c
e
 (
%
 o
f 
c
o
n
tr
o
l)
0 .0 0 0 1 0 .0 0 1 0 .0 1 0 .1 1 1 0 1 0 0
0
5 0
1 0 0
1 5 0
2 0 0
  4 0 0  A 3 7 5
 21 
B. 
R A L O X IF E N E   (9 6 H R S )
R a lo x i fe n e   (u M )
B
io
lu
m
in
e
s
c
e
n
c
e
 (
%
 o
f 
c
o
n
tr
o
l)
0 .0 0 0 1 0 .0 0 1 0 .0 1 0 .1 1 1 0 1 0 0
0
5 0
1 0 0
1 5 0
  4 0 0  A 3 7 5
T O R E M IF E N E   (9 6 H R S )
T o r e m i fe n e (u M )
B
io
lu
m
in
e
s
c
e
n
c
e
 (
%
 o
f 
c
o
n
tr
o
l)
0 .0 0 0 1 0 .0 0 1 0 .0 1 0 .1 1 1 0 1 0 0
0
5 0
1 0 0
1 5 0
2 0 0
  4 0 0  A 3 7 5
 
O H T   (9 6 H R S )
O H T   (u M )
B
io
lu
m
in
e
s
c
e
n
c
e
 (
%
 o
f 
c
o
n
tr
o
l)
0 .0 0 0 1 0 .0 0 1 0 .0 1 0 .1 1 1 0 1 0 0
0
5 0
1 0 0
1 5 0
  4 0 0  A 3 7 5
F U L V E S T R A N T   (9 6 H R S )
F u lv e s tr a n t  (u M )
B
io
lu
m
in
e
s
c
e
n
c
e
 (
%
 o
f 
c
o
n
tr
o
l)
0 .0 0 0 1 0 .0 0 1 0 .0 1 0 .1 1 1 0 1 0 0
0
5 0
1 0 0
1 5 0
2 0 0
  4 0 0  A 3 7 5
  
L A P A T IN IB   (7 2  H R S )
L a p a tin ib   (u M )
B
io
lu
m
in
e
s
c
e
n
c
e
 (
%
 o
f 
c
o
n
tr
o
l)
0 .0 0 0 1 0 .0 0 1 0 .0 1 0 .1 1 1 0 1 0 0
0
5 0
1 0 0
1 5 0
2 0 0
  4 0 0  A 3 7 5
  
M E L P H A L A N   (4 8 H R S )
M e lp h a la n   (u M )
B
io
lu
m
in
e
s
c
e
n
c
e
 (
%
 o
f 
c
o
n
tr
o
l)
0 .0 0 0 1 0 .0 0 1 0 .0 1 0 .1 1 1 0 1 0 0
0
5 0
1 0 0
1 5 0
2 0 0
  4 0 0  A 3 7 5
 
S O R A F E N IB   (7 2  H R S )
S o r a fe n ib   (u M )
B
io
lu
m
in
e
s
c
e
n
c
e
 (
%
 o
f 
c
o
n
tr
o
l)
0 .0 0 0 1 0 .0 0 1 0 .0 1 0 .1 1 1 0 1 0 0
0
5 0
1 0 0
1 5 0
  4 0 0  A 3 7 5
C R IZ O T IN IB   (7 2 H R S )
C r i z o tin ib   (u M )
B
io
lu
m
in
e
s
c
e
n
c
e
 (
%
 o
f 
c
o
n
tr
o
l)
0 .0 0 1 0 .0 1 0 .1 1 1 0 1 0 0
‐ 5 0
0
5 0
1 0 0
1 5 0
  4 0 0  A 3 7 5
J Q 1   (7 2 H R S )
J Q 1   (u M )
B
io
lu
m
in
e
s
c
e
n
c
e
 (
%
 o
f 
c
o
n
tr
o
l)
0 .0 0 0 1 0 .0 0 1 0 .0 1 0 .1 1 1 0 1 0 0
0
5 0
1 0 0
1 5 0
2 0 0
  4 0 0  A 3 7 5
E R L O T IN IB   (7 2 H R S )
E r lo tin ib   (u M )
B
io
lu
m
in
e
s
c
e
n
c
e
 (
%
 o
f 
c
o
n
tr
o
l)
0 .0 0 0 1 0 .0 0 1 0 .0 1 0 .1 1 1 0 1 0 0
0
5 0
1 0 0
1 5 0
  4 0 0  A 3 7 5
 22 
C 
  
  
E P IR U B IC IN   (4 8 H R S )
E p i r u b ic in   (u M )
B
io
lu
m
in
e
s
c
e
n
c
e
 (
%
 o
f 
c
o
n
tr
o
l)
0 .0 0 0 1 0 .0 0 1 0 .0 1 0 .1 1 1 0 1 0 0
0
5 0
1 0 0
1 5 0
  4 0 0  A 3 7 5
D O X O R U B IC IN   (4 8 H R S )
D o x o ru b ic in   (u M )
B
io
lu
m
in
e
s
c
e
n
c
e
 (
%
 o
f 
c
o
n
tr
o
l)
0 .0 0 0 0 1 0 .0 0 0 1 0 .0 0 1 0 .0 1 0 .1 1 1 0
0
5 0
1 0 0
1 5 0
  4 0 0  A 3 7 5
 
 
 
Figure 4: Drug Selection 
Twenty-four known anti-cancer drugs were tested on A375 cells.  Various 
concentrations were used in order to generate a dose-response curve to look for 
A375 cell killing compared against a no drug control.  Graphpad Prism 6 was 
used to generate the dose-response curves. (A) Drugs that showed no or little 
killing of A375 cells. (B) Drugs that showed A375 cell killing at high doses. (C) 
Drugs that showed killing even at lower doses. 
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selected from the category of drugs that showed a pronounced effect on A375 
cells at lower doses.  In addition to these, both crizotinib and bortezomib were 
also used.  Each drug was individually dosed and then read at 24, 48, 72, or 96 
hours to generate dose response curves.  The results for each curve were 
normalized to their respective no drug control.  (A) Dose response curves in the 
presence and absence of CCD13LU stromal cells were created for the seven 
drugs.  Bortezomib, crizotinib, epirubicin, gemcitabine, and paclitaxel did not 
show any changes in drug response in the presence of CCD13LU cells. Cells 
treated with cytarabine at low doses (up to 0.0005µM) showed a slight stromal 
cell-mediated resistance to this agent in the presence of CCD13LU cells.  At 
higher doses no resistance was observed.  Vemurafenib was subject to slight 
resistance when cells were treated in the presence of CCD13LU cells. (B) Dose 
response curves were also created for A375 when co-cultured with HS888LU.  
Crizotinib, cytarabine, epirubicin, gemcitabine, and paclitaxel all showed no 
significant differences in response when co-cultured with HS888LU.  Bortezomib 
showed very slight sensitization for A375 killing at 0.03 µM.  Vemurafenib had 
slightly reduced killing on A375 in the presence of HS888LU. (C) Dose response 
curves were also created for A375 when co-cultured with LL86.  It did not appear 
that co-culture with LL86 led to significant drug resistance or sensitization for any 
of the seven compounds tested. 
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Figure 5: Dose Response Curves with CCD13LU Cells for Selected Drugs 
Seven drugs were tested on A375 cells in the presence of CCD13LU cells.  
Various concentrations were used in order to generate a dose-response curve to 
look for A375 cell killing compared to a no drug control.  Dose-response curves 
for A375 cells in the presence and absence of stroma were superimposed on the 
same graph to show differences between the two.  Graphpad Prism 6 was used 
to generate the dose response curves. 
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Figure 6: Dose Response Curves with HS888LU Cells for Selected Drugs 
Seven drugs were tested on A375 cells in the presence of HS888LU cells.  
Various concentrations were used in order to generate a dose-response curve to 
look for A375 cell killing compared to a no drug control.  Dose-response curves 
for A375 cells in the presence and absence of stroma were superimposed on the 
same graph to show differences between the two.  Graphpad Prism 6 was used 
to generate the dose response curves. 
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Figure 7: Dose Response Curves with LL86 Cells for Selected Drugs 
Seven drugs were tested on A375 cells in the presence of LL86 cells.  Various 
concentrations were used in order to generate a dose-response curve to look for 
A375 cell killing compared to a no drug control.  Dose-response curves for A375 
cells in the presence and absence of stroma were superimposed on the same 
graph to show differences between the two.  Graphpad Prism 6 was used to 
generate the dose response curves. 
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DISCUSSION 
 This study demonstrated that certain drugs do behave differently on the 
melanoma cell line A375 in the presence versus absence of stromal cells.  Some 
key findings of this study include: (i) Vorinostat appears to have an increased 
effect on A375 cells in the presence of stromal cells. (ii) Procarbazine HCL has 
significantly less killing efficiency in the presence of CCD1065SK or CCD13LU 
cells. (iii) Paclitaxel, gemcitabine, docetaxel, cytarabine, epirubicin, doxorubicin, 
and vemurafenib all showed significant killing of A375 cells even at low doses. 
(iv) Of these drugs, only vemurafenib and cytarabine showed some reduced 
efficacy on A375 in the presence of stromal cells.  These findings suggest that 
stromal cells influence the melanoma cell drug response. 
 
FDA Oncology Screen  
 In order to get a comprehensive assessment of the potential of stromal 
cells to influence melanoma cell drug response to diverse established anti-tumor 
agents, while simultaneously identifying new drugs of interest, a screen using 
FDA approved oncology plates was performed.  While not all of the compounds 
included in this analysis are used clinically for melanoma treatment, they are all 
used (or have been approved in the past) as cancer chemotherapeutics for 
various neoplasias.  Eighty-one different compounds at two different 
concentrations and with two different stromal lines a few drugs of interest were 
identified.  Of the eighty-one compounds, four drugs were identified to be of the 
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most interest.  A drug with notable results was procarbazine HCL.  The effects of 
procarbazine HCL were diminished significantly in the presence of both 
CCD1065SK as well as CCD13LU cells.   In the absence of stroma cells, A375 
proliferation was on average across all four different conditions, 10.6% compared 
to the no drug control (100%).  In the presence of stroma, the average survival 
percentage across the four different conditions was 102%.  An average 
difference of over 90% survival was the largest margin of resistance seen for any 
drug during this study.  Procarbazine HCL, more commonly known as Matulane, 
is a hydrazine derivative anti-neoplastic agent.  As an alkylating agent, the drug 
impairs DNA and RNA synthesis.  Specifically it is thought to impair trans-
methylation of methionine and thus leads to inactive t-RNA.[18] The drug is 
typically used to treat Hodgkin’s lymphoma however presently other therapeutic 
options for this agent are being explored.   
 Another drug that showed some resistance in the presence of stromal 
cells was dasatinib.  A375 showed resistance to dasatinib at both concentrations 
and for both doses.  While not as pronounced as in the case of procarbazine 
HCL there still seemed to be a decrease in activity of dasatinib in the presence of 
stromal cells.  Dasatinib is FDA-approved for the treatment of Chronic Myeloid 
Leukemia.[19]  
 Some drugs showed greater killing in the presence of stroma.  One such 
drug was vorinostat.  Vorinostat is an HDAC inhibitor that is generally used to 
treat cutaneous T cell lymphoma.[20] This drug is of particular interest as 
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vorinostat has been proven to be effective against melanoma.  Not only has this 
been effective in cutaneous melanoma but also as a treatment for uveal 
melanoma.[21, 22]   
 One last drug on interest identified from this experiment was tamoxifen 
citrate.  Also known as Nolvadex, tamoxifen citrate is a precursor that gets 
metabolized to hydroxytamoxifen.  Tamoxifen is an estrogen receptor antagonist 
and has been shown to be effective in treating breast cancer.[23] The largest 
increase in drug effectiveness was seen in the presence of CCD1065SK cells at 
0.5 micromolar.  Interestingly enough, when combined with CCD1065SK cells at 
0.1 micromolar the drug was less effective then when treated on A375 alone. 
  
Identification of compounds effective against A375 
 In order to determine which drugs were effective at killing A375 cells, a 
screen using 24 different cancer drugs were used at multiple doses against 
A375.  The first compounds identified were those that had no effect on A375 
killing.  These drugs included dexamethasone, bicalutamide, MDV3100, cisplatin, 
lenalidomide, 5-fluoracil, and pomalidomide.  None of these drugs had any effect 
on A375 cell death.  Interestingly enough dexamethasone even increased 
proliferation at higher doses.  This was expected as dexamethasone is a 
glucocorticoid that has been known to stimulate melanin production.  As seen in 
a study by Tang et al., A375 cells are known to have a slight increase in 
proliferation when treated with dexamethasone.[24] Also as expected, anti-
 30 
angiogenic thalidomide derivatives such as lenalidomide and pomalidomide had 
no effect on A375 cell killing, as the cells have not developed into a tumor.  
Bicalutamide and MDV100, androgen receptor antagonists also had no effect 
even up to 10 micromolar suggesting that this pathway does not play a significant 
role in A375 cell signaling and growth pathways.  Cisplatin also had little effect on 
A375 cells.  It has been hypothesized that endogenous nitric oxide helps the cell 
to evade Cisplatin induced apoptosis and could perhaps explain a lack of effect. 
[25] 
 The most interesting drug in this group was 5-fluoracil.  Of the drugs in this 
category 5-fluoracil is the drug most commonly prescribed for skin cancer.  5-
fluoracil can be used topically to treat basal cell carcinomas (the most common 
type of cancer).[26] Acting as pyrimidine analog, the drug interferes with DNA 
synthesis and eventually leads to apoptosis.[26] However, it had little effect on 
A375 cells. 
 The next group of compounds were the drugs that showed killing of A375 
only at higher doses.  Of these 10 compounds, 4 can be categorized as anti-
estrogens.  Raloxifene, OHT, toremifene, and fulvestrant are estrogen receptor 
antagonists.  It has been documented that estrogen receptors play a potential 
role in melanoma, including the process of metastasis. [27] Most of these 
compounds started killing A375 cells between 0.1 and 1 micromolar, with 
toremifene and raloxifene being slightly more effective in that range. 
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 The next class of compounds to make up a majority of the high dose 
responders include the kinase inhibitors.  These include: sorafenib, lapatinib, 
erlotinib, and crizotinib.    Of these, crizotinib and sorafenib were the most 
effective at A375 killing.  Sorafenib is of particular interest because like 
vemurafenib, it can inhibit the Raf kinases.  Sorafenib however is more likely to 
bind and inhibit CRAF than BRAF.[7] At higher doses both are inhibited and this 
can explain the observation of more killing at higher doses.  Lapatinib and 
erlotinib are both EGFR inhibitors and only started to kill A375 cells at doses 
above 1 micromolar.  The last two drugs in this category include JQ1 and 
melphalan.  Melphalan has had mixed reviews in regards to therapeutic uses for 
melanoma.  Some studies have shown effectiveness while others claim the drug 
has little use.[28] 
 The last group of drugs were the drugs that significantly killed A375 cells, 
even at lower doses (as low as 0.0003 micromolar).  These drugs included 
paclitaxel, docetaxel, epirubicin, gemcitabine, cytarabine, and doxorubicin.  
Paclitaxel and docetaxel are both potent anti-mitotics that interfere with 
microtubule assembly and thus cell division.[29] Docetaxel proved to be the most 
effective drug at killing A375 cells (along with gemcitabine).  Docetaxel is known 
to be effective in treatment for metastatic melanoma.[30] The remaining drugs 
(gemcitabine, doxorubicin, epirubicin, and cytarabine) all interfere with DNA 
synthesis.  Interestingly, none seem to be effective in patients with metastatic 
melanoma.[31, 32] 
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Stromal Co-culture with A375 Selective Drugs 
 
After the compounds which proved to be effective at killing A375 were 
identified, the next step was to determine if any of these drugs (as well as 
bortezomib and crizotinib) showed added or reduced activity on A375 in the 
presence of three different stromal cell lines.  The three stromal cell lines that 
were selected were CCD13LU, HS888LU, and LL86.  CCD13LU, HS888LU, and 
LL86 are all human lung fibroblasts.  The main reason for why these cell lines 
were chosen was that they had been used in a previous study by Straussman 
that tried to determine differences in melanoma cell drug response in the 
presence of various stromal lines. [16] These cell lines were able to significantly 
rescue some melanoma lines from vemurafenib.   This was determined to be an 
effect of the high levels of HGF that these cell lines produced.   However in 
regards to A375, they were unable to cause significant resistance to 
vemurafenib. For this study, we hoped to determine if these cell lines could have 
an affect on any of the other drugs that showed significant killing on A375 cells. 
 We tested the chosen cell lines in the presence of CCD13LU cells.   
Bortezomib, gemcitabine, crizotinib, epirubicin, and paclitaxel showed no 
significant change in killing when in the presence of CCD13LU.  Interestingly, 
CCD13LU cells seemed to increase A375 proliferation when treated with 
cytarabine at lower doses (0.001-0.005 micromolar). However at levels at or 
higher than 0.01 micromolar, the two curves were no longer significantly different.  
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Also as expected CCD13LU cells had a slight rescue effect on A375 cells when 
the latter were treated with vemurafenib.  This was expected, and had been 
previously seen. (Straussman et al.) 
 The second stromal line that was evaluated was HS888LU.  
HS888LU seemed to slightly increase the effectiveness of bortezomib at both 
lower and higher doses.  One study that involved bortezomib and HGF has 
shown that patients suffering from multiple myeloma with higher levels of HGF 
respond worse to bortezomib when they had higher levels of HGF.[33] This 
suggests that HS888LU potentially secretes another cytokine or growth factor 
that increases the effectiveness of bortezomib.  Vemurafenib also had a slightly 
reduced effect on A375 in the presence of HS888LU.  This was also expected 
and can be attributed to the higher levels of HGF.  The rest of the drugs tested 
did not seem to respond differently in the presence of HS888LU. 
 The last stromal line tested was LL86.  Interestingly, LL86 did not 
have an effect on any of the drugs tested.   
 
Limitations to the Study 
 
 Having compiled these data, it is understood that some additional studies 
could have made this study more insightful.  For example, it would have been of 
interest to conduct a much larger screen of compounds with more stromal cell 
lines.  For this study, only lung and skin fibroblasts were used primarily because 
melanoma mainly originates in the skin and the lungs are a major site of 
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metastasis.  It could be of interest to see how liver fibroblasts, astrocytes, or 
fibroblasts of other organs might affect melanoma cell drug response.  Another 
limitation of this study was that only one melanoma line was tested.  For follow-
up studies, it would be valuable to compare different types of melanoma cell lines 
and how they respond differently to drugs in the presence of absence of stroma.  
Ideally at least one cell line would be wild type for BRAF mutation status.  This 
could lead to additional studies of interest especially in regards to vemurafenib 
and other BRAF mutant selective drugs.   Additionally several follow-up 
mechanistic experiments could have been completed. 
 
Ideas for Future Studies 
 As previously indicated, perhaps the most important future study would be 
to screen for candidate anti-cancer drugs in the presence of higher numbers of 
stromal lines.  Specifically, stromal lines from organs/tissues which melanoma is 
known to frequently metastasize to.  For instance, testing more lung fibroblasts, 
hepatocytes, astrocytes, and other accessory cells could yield interesting results.   
Another idea is to determine exactly how the stromal cells are affecting drug 
response.  As seen in the study of Straussman et al, they were able to identify 
HGF as the main mediator for stromal cell-mediated resistance to vemurafenib in 
a variety of melanoma cell lines.  However it may be possible that other growth 
factors or cytokines are responsible for altered drug response in other stromal 
cell lines.  By identifying exactly what molecule(s) are conferring drug resistance 
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or sensitization, it would be much easier to identify targets for possible 
therapeutic interventions.  One last idea for future studies include using a wider 
variety of doses.  As seen in the experiments of the current study, some doses 
showed a difference in activity while other doses for the same experimental 
conditions showed no change in drug activity at all. 
Conclusion 
 In this study we wanted to observe if stromal cell-mediated alterations in 
drug response played a significant role in melanoma.  By first developing a 
screen of a large number of compounds using multiple stromal cell lines we were 
able to identify a few compounds which showed a significant amount of altered 
drug activity in the presence versus the absence of stromal cells.  Procarbazine 
HCL, tamoxifen citrate, vorinostat, and dasatinib showed the most dramatic 
changes in activity when exposed to the presence of stromal cells.  Then, after 
selecting for drugs that showed significant A375 killing, we were able to generate 
dose response curves in the presence versus absence of stroma in order to 
observe stromal mediated changes in A375 drug response.  We found that 
vemurafenib, bortezomib, and cytarabine showed the largest changes in drug 
activity when in the presence of stroma. 
 As seen by this study, stromal cells can significantly alter melanoma cell 
drug response.  This fact has numerous implications for studies involving 
acquired tumor resistance to chemotherapy, as well as overall tumorigenesis.  
We consider that further study needs to be done to identify the effects of human 
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stromal lines on cancer development. Based on our observations in this study, 
we also propose that current models for drug identification need to account for 
stromal mediated changes in drug response in order to more accurately estimate 
how anti-cancer drugs may perform in vivo.  
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